Skip to main content
main-content

SGLT2 inhibitors


Browse the latest news, expert commentary, and educational content on the SGLT2 inhibitor medication class.


Highlights

06-10-2021 | Adverse effects | News

Steep eGFR drop on SGLT2 inhibitor initiation may pose cardiorenal risk

The small proportion of people who experience an eGFR fall of more than 30% on starting an SGLT2 inhibitor may be at increased risk for adverse outcomes, research suggests.

05-28-2021 | Empagliflozin | News

Empagliflozin gets positive CHMP decision for heart failure

Click through to read more on this announcement

05-17-2021 | ACC 2021 | Conference coverage | News

Heart failure benefits of sotagliflozin consistent in preserved ejection fraction

The protective effect of sotagliflozin in people with type 2 diabetes and heart failure extends to those who have preserved ejection fraction, shows a prespecified pooled analysis of SOLOIST-WHF and SCORED.

SGLT2 inhibitor use in type 2 diabetes management

Learn about prescribing these medications with guidance from the Improving Diabetes Steering Committee.

  • » A prescribing tool to inform prescribing decisions for SGLT2 inhibitors
  • » SGLT2 inhibitors: Key evidence and implications for clinical practice
  • » Translating SGLT2 inhibitor cardiovascular evidence into practice
  • » This content is intended only for UK healthcare providers and was made possible by educational funding provided by Napp Pharmaceuticals Ltd.

More on SGLT2 inhibitors

Stay informed with Medicine Matters

Get the latest developments in diabetes delivered straight to your inbox

Image Credits